Search

To evaluate the resistant strains selection during treatment with cefmenoxime, a 3rd generation cephalosporin, 10 adult inpatients of an intensive-care unit had quantitative stool cultures, before the treatment, on the 7-10th day of therapy, and 7-10 days after the end of the antibiotic course. The results show that the selecting effect of cefmenoxime is not different from the effect previously observed for cefotaxime.

Cefmenoxime (CMX) has been administered under parenteral injection to 39 neonates delivered at term, nearly always by monotherapy in an average dosage of 86.8 mg/kg/day. CMX has been used 31 times in first line therapy and 8 times after failure of association Ampicillin-Gentamicin. 25 strains have been identified: 16 E. coli (9 Ampicillin resistant), 7 P. mirabilis (1 Ampicillin resistant), 1 K. oxytoca and 1 Streptococcus B. The neonates group with septicaemia (1 with arthritis) has been cured without after-effects as urinary tract infections and systemic infections. 2 respiratory tract infections have been improved, the others have been cured. Bacterial samples have always been sterilized within 2 days. Local tolerance (IV or/and IM injection) has been very good. No clinical or biological abnormality has been imputed to treatment. Cefmenoxime appears very effective on enterobacteriaceae (MIC range 0.05-0.5 mg/l) and can be used in newborn infections.